48
Participants
Start Date
May 5, 2025
Primary Completion Date
October 31, 2026
Study Completion Date
December 31, 2028
orelabrutinib combined with the Pola-R-CHP regimen
Enrolled patients will receive six cycles of orelabrutinib in combination with the Pola-R-CHP regimen, with each 21-day period being one cycle. At the end of the six cycles, an interim efficacy evaluation will be conducted. Patients with a response of CR or PR will receive an additional two cycles of orelabrutinib in combination with rituximab and undergo a final efficacy evaluation. Patients with a response of CR/PR after eight cycles of induction therapy will receive maintenance treatment with orelabrutinib for up to two years.
RECRUITING
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
The Second Affiliated Hospital of Jiaxing University
OTHER
Taizhou First People's Hospital
OTHER
Huzhou Central Hospital
OTHER
Zhejiang Cancer Hospital
OTHER
Dongyang People's Hospital
OTHER
Yuyao People's Hospital
OTHER
Taizhou Central Hospital affiliated to Taizhou University
UNKNOWN
Shaoxing Central Hospital
OTHER
Affiliated Hospital of Jiaxing University
OTHER
Shaoxing People's Hospital
OTHER
The Central Hospital of Lishui City
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Ningbo People's Hospital
UNKNOWN
The People's Hospital of Quzhou
OTHER
Zhuji People's hospital
UNKNOWN
Affiliated Hangzhou First People's Hospital
UNKNOWN
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER